ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Merck & Co., Inc. (MRK) Flushing Drug May Tackle Baldness


3/22/2012 7:00:55 AM

Male-pattern baldness may be caused by a protein in the scalp, according to research that raises the possibility drugs being tested by Merck & Co. (MRK) and Actelion Ltd. (ATLN) for other uses might prevent hair loss. Bald spots had an excessive amount of a protein called prostaglandin D2 or PGD2, according to a study in Science Translational Medicine. Merck’s experimental treatment for facial flushing and Actelion’s allergy compound, both in late- stage studies, block the protein.

Read at Bloomberg
Read at HealthDay
Read at BBC News
Read at ScienceDaily
Read at EurekAlert!
Read at MedicalXpress
 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES